222 related articles for article (PubMed ID: 17539951)
21. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.
Prosperini L; Giannì C; Barletta V; Mancinelli C; Fubelli F; Borriello G; Pozzilli C
J Neurol Sci; 2012 Dec; 323(1-2):104-12. PubMed ID: 23006974
[TBL] [Abstract][Full Text] [Related]
22. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P;
N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952
[TBL] [Abstract][Full Text] [Related]
23. Real-world use of cladribine tablets (completion rates and treatment persistence) in patients with multiple sclerosis in England: The CLARENCE study.
Brownlee W; Amin A; Ashton L; Herbert A
Mult Scler Relat Disord; 2023 Nov; 79():104951. PubMed ID: 37639781
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.
Giovannoni G; Soelberg Sorensen P; Cook S; Rammohan KW; Rieckmann P; Comi G; Dangond F; Hicking C; Vermersch P
Mult Scler; 2019 May; 25(6):819-827. PubMed ID: 29716436
[TBL] [Abstract][Full Text] [Related]
25. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.
Leist TP; Comi G; Cree BA; Coyle PK; Freedman MS; Hartung HP; Vermersch P; Casset-Semanaz F; Scaramozza M;
Lancet Neurol; 2014 Mar; 13(3):257-67. PubMed ID: 24502830
[TBL] [Abstract][Full Text] [Related]
26. Impact of cladribine on soluble adhesion molecules in multiple sclerosis.
Mitosek-Szewczyk K; Stelmasiak Z; Bartosik-Psujek H; Belniak E
Acta Neurol Scand; 2010 Dec; 122(6):409-13. PubMed ID: 20175758
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
Giovannoni G; Soelberg Sorensen P; Cook S; Rammohan K; Rieckmann P; Comi G; Dangond F; Adeniji AK; Vermersch P
Mult Scler; 2018 Oct; 24(12):1594-1604. PubMed ID: 28870107
[TBL] [Abstract][Full Text] [Related]
28. Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis.
Sipe JC
Expert Rev Neurother; 2010 Mar; 10(3):365-75. PubMed ID: 20187859
[TBL] [Abstract][Full Text] [Related]
29. Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy.
Lizak N; Hodgkinson S; Butler E; Lechner-Scott J; Slee M; McCombe PA; Shaw C; Skibina O; Vucic S; Shuey N; Barnett MH; Parratt J; Butzkueven H; Jack D; Fabris J; Kalincik T
Mult Scler; 2021 Mar; 27(3):465-474. PubMed ID: 32530363
[TBL] [Abstract][Full Text] [Related]
30. [Mitoxantrone as induction therapy in aggressive relapsing remitting multiple sclerosis: a descriptive analysis of 100 consecutive patients].
Le Page E; Leray E; Taurin G; Coustans M; Chaperon J; Edan G
Rev Neurol (Paris); 2006 Feb; 162(2):185-94. PubMed ID: 16518258
[TBL] [Abstract][Full Text] [Related]
31. Cladribine for multiple sclerosis.
Drug Ther Bull; 2018 Feb; 56(2):21-24. PubMed ID: 29449328
[TBL] [Abstract][Full Text] [Related]
32. Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis.
Sormani MP; Li DK; Bruzzi P; Stubinski B; Cornelisse P; Rocak S; De Stefano N
Neurology; 2011 Nov; 77(18):1684-90. PubMed ID: 21975200
[TBL] [Abstract][Full Text] [Related]
33. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?
Barkhof F; Hulst HE; Drulovic J; Uitdehaag BM; Matsuda K; Landin R;
Neurology; 2010 Mar; 74(13):1033-40. PubMed ID: 20200338
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of mitoxantrone in pediatric patients with aggressive multiple sclerosis.
Etemadifar M; Afzali P; Abtahi SH; Ramagopalan SV; Nourian SM; Murray RT; Fereidan-Esfahani M
Eur J Paediatr Neurol; 2014 Mar; 18(2):119-25. PubMed ID: 24139067
[TBL] [Abstract][Full Text] [Related]
35. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis.
Stein MS; Liu Y; Gray OM; Baker JE; Kolbe SC; Ditchfield MR; Egan GF; Mitchell PJ; Harrison LC; Butzkueven H; Kilpatrick TJ
Neurology; 2011 Oct; 77(17):1611-8. PubMed ID: 22025459
[TBL] [Abstract][Full Text] [Related]
36. Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis.
Krishnan C; Kaplin AI; Brodsky RA; Drachman DB; Jones RJ; Pham DL; Richert ND; Pardo CA; Yousem DM; Hammond E; Quigg M; Trecker C; McArthur JC; Nath A; Greenberg BM; Calabresi PA; Kerr DA
Arch Neurol; 2008 Aug; 65(8):1044-51. PubMed ID: 18541787
[TBL] [Abstract][Full Text] [Related]
37. Cladribine: mode of action and implications for treatment of multiple sclerosis.
Leist TP; Weissert R
Clin Neuropharmacol; 2011; 34(1):28-35. PubMed ID: 21242742
[TBL] [Abstract][Full Text] [Related]
38. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study.
Zanetta C; Rocca MA; Meani A; Martinelli V; Ferrè L; Moiola L; Filippi M
J Neurol; 2023 Jul; 270(7):3553-3564. PubMed ID: 37027018
[TBL] [Abstract][Full Text] [Related]
40. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
